Antagonizing Dabigatran by Idarucizumab in Cases of Ischemic Stroke or Intracranial Hemorrhage in Germany – Updated Series of 120 Cases: Pawel Kermer
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
Antagonizing Dabigatran by Idarucizumab in Cases of Ischemic Stroke or Intracranial Hemorrhage in Germany – Updated Series of 120 Cases: Pawel Kermer
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Patients with acute ischemic stroke on dabigatran treatment may become eligible for thrombolysis with rt-PA. In patients on dabigatran with intracerebral hemorrhage idarucizumab could prevent lesion growth. Carmen Lahiff-Jenkins, Managing Editor of the International Journal of Stroke spoke to Dr Pawel Kermer from Krankenhaus Sanderbusch; Neurology, Sande Germany.
Read the article link here
Pas encore de commentaire